Interim analysis of a three-arm phase 3 trial in 203 women with HER2-negative metastatic breast cancer and germline BRCA1/2 mutations: median PFS was 11.0 months with fuzuloparib-apatinib, 6.7 with fuzuloparib and 3.0 with chemotherapy.
RCTn = 203 women
Li et al. Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial